RT Journal Article
SR Electronic
T1 Systematic single-variant and gene-based association testing of 3,700 phenotypes in 281,850 UK Biobank exomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.19.21259117
DO 10.1101/2021.06.19.21259117
A1 Karczewski, Konrad J.
A1 Solomonson, Matthew
A1 Chao, Katherine R.
A1 Goodrich, Julia K.
A1 Tiao, Grace
A1 Lu, Wenhan
A1 Riley-Gillis, Bridget M.
A1 Tsai, Ellen A.
A1 Kim, Hye In
A1 Zheng, Xiuwen
A1 Rahimov, Fedik
A1 Esmaeeli, Sahar
A1 Jason Grundstad, A.
A1 Reppell, Mark
A1 Waring, Jeff
A1 Jacob, Howard
A1 Sexton, David
A1 Bronson, Paola G.
A1 Chen, Xing
A1 Hu, Xinli
A1 Goldstein, Jacqueline I.
A1 King, Daniel
A1 Vittal, Christopher
A1 Poterba, Timothy
A1 Palmer, Duncan S.
A1 Churchhouse, Claire
A1 Howrigan, Daniel P.
A1 Zhou, Wei
A1 Watts, Nicholas A.
A1 Nguyen, Kevin
A1 Nguyen, Huy
A1 Mason, Cara
A1 Farnham, Christopher
A1 Tolonen, Charlotte
A1 Gauthier, Laura D.
A1 Gupta, Namrata
A1 MacArthur, Daniel G.
A1 Rehm, Heidi L.
A1 Seed, Cotton
A1 Philippakis, Anthony A.
A1 Daly, Mark J.
A1 Davis, J. Wade
A1 Runz, Heiko
A1 Miller, Melissa R.
A1 Neale, Benjamin M.
YR 2021
UL http://medrxiv.org/content/early/2021/07/02/2021.06.19.21259117.abstract
AB This manuscript has been temporarily withdrawn by the authors upon request from UK Biobank. Results supporting this manuscript remain valid and can be found at https://genebass.org. The full manuscript will be re-uploaded pending decision by UK Biobank. If you have any questions, please contact the corresponding author.Competing Interest StatementKJK is a consultant for Vor Biopharma. BRG, XZ, FR, SE, AJG, MR, JW, HJ, JWD are employees of AbbVie Inc. MR is an employee of and owns stock in AbbVie Inc. EAT, DS, PGB, HR are employees of Biogen and hold stocks/stock options in Biogen. HK, XC, XH and MRM are employees of Pfizer. DK holds stock in the private company TriNetX, LLC. DSP was an employee of Genomics plc. All the analyses reported in this paper were performed as part of DSP's previous employment at the Massachusetts General Hospital and Broad Institute. NAW owns stock in Pfizer. LDG receives funding from Intel and Illumina. DGM is a founder with equity of Goldfinch Bio, and serves as a paid advisor to GSK, Variant Bio, Insitro, and Foresite Labs. HLR is a member of the scientific advisory board at Genome Medical. AAP is a Venture Partner at GV. He has received consulting fees from Novartis, and receives funding from Bayer, IBM, Microsoft, Alphabet, Intel, GSK, Pfizer, Illumina. MJD is a founder of Maze Therapeutics. BMN is a member of the scientific advisory board at Deep Genomics and RBNC Therapeutics, member of the scientific advisory committee at Milken and a consultant for Camp4 Therapeutics, Merck and Biogen.Funding StatementThis work was funded by Abbvie, Biogen, and Pfizer, who are represented by co-authors on this manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank applications 26041 and 48511All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available at https://genebass.orghttps://genebass.org